Overview

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This is a two part introductory clinical trial with MK-5478. Part I will evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of MK-5478 in young, healthy males. Part II will evaluate the safety, tolerability and pharmacodynamic effects of MK-5478 in participants with hypertension. The primary hypothesis is that single oral doses of MK-5478 are sufficiently safe and well tolerated.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Candesartan
Candesartan cilexetil